29. 29
3D conformal radiotherapy
is the minimal standard of technique
in HNSCC.
Renzo Corvo. Evidence-based radiation oncology in head and neck squamous cell
carcinoma. Radiotherapy and Oncology 2007;85:156-170
67. INT-026: A Phase III Trial
of Chemoradiotherapy in Unresectable Patients
• Median f/u: 41 mos.
• 3-year OS and median survival
– RT: 23%, 12.6 mos.
– CDDP/RT: 37%, 19.1 mos.
A
B
C
CDDP/RT vs. RT
P = 0.014
Adelstein et al: JCO, 2003; 21:92-98.
70. Σ
Τ
Υ
Α
Ι
Ο
Π
Ο
Ι
Η
Η
ΑΚΘ/ΥΜΘ
(CDDP+5FU x 2) + 66 Gy
Υεηξνπξγείν + ΑΚΘ
(60 Gy to 70 Gy)
Μέζε παξαθνινύζεζε: 6 ρξόληα
Soo et al, Br J Cancer 2005
Κακία δηαθνξά ζην DFS (50% vs. 40%)
ηάδηα III/IV H
& N SCC
ηνκαην-
θάξπγγαο
21%
73. ΑΚΘ/ΥΜΘ, Δπηβίσζε ζε ζρέζε κε
ηελ ειηθία
24% + 4
22% + 4
12% + 4
3% + 9
Age < 50
Age 51-60
Age 61-70
Age > 71
Meta-Analysis of Chemotherapy
in Head & Neck Cancer
MACH-NC
74. Bonner et al. NEJM, 2006
Stage III/IV SCC
Oropharynx
Larynx
Hypopharynx
R
A
N
D
O
M
I
Z
E
Arm 1 :
RT
(QD, BID, Conc Boost)
Arm 2 :
RT (QD, BID, Conc
Boost)
Weekly
Cetuximab
400 mg/m2 δόζε θόξησζεο
250 mg/m2 εβδνκαδηαία δόζε
Endpoint RT RT+C225 P
Median Survival 29 mo 49 mo 0.02
2 yr Survival 55% 62% 0.02
3 yr Survival 44% 57% 0.02
3 yr Survival
Oropharynx
30.3 mo 66 mo
G ¾ Mucositis 52% 55% 0.5
G ¾ Skin reaction 18% 34% 0.0003
Βηνινγηθά ζηνρεπκέλε ζεξαπεία
ΑΚΘ/Cetuximab Vs ΑΚΘ
76. Phase III Trial of
Radiotherapy plus Cetuximab
Versus
Radiotherapy plus Cisplatin
In HPV-Associated Oropharynx Cancer
RTOG 1016
77. Eligibility:
- Locoregionally advanced HNC
- Treatment naïve
R
A
N
D
O
M
I
Z
E
Enrollment: 400 patients (200 each arm)
Primary Objective: Overall Survival
TPF INDUCTION – 6 weeks
(repeated every 21 days for 2 cycles)
Docetaxel
75mg/m2
Cisplatin
75mg/m2
5-FU
750mg/m2
Day 1 Day 2 Day 3 Day 4 Day 5
Docetaxel
25mg/m2
5-Fluorouracil
600mg/m2
Hydroxyurea
500mg
Radiation
150cGy Hyperfx.
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 TO Day14
Docetaxel
25mg/m2
5-Fluorouracil
600mg/m2
Hydroxyurea
500mg
Radiation
150cGy Hyperfx.
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 TO Day14
NO INDUCTION
DFHX Chemoradiotherapy – 10 weeks
(week on/ week off - for 5 cycles)
DFHX Chemoradiotherapy – 10 weeks
(week on/ week off - for 5 cycles )
Off week –
no treatment
Off week –
no treatment
DeCIDE - Phase III Induction Trial